Kasper Tore Vinten

Kasper Tore Vinten

Auto-generated profile, based on publicly available information

Kasper Tore Vinten

Laboratory Genetic Metabolic Diseases, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 October 2025 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
KVKasper T. Vinten
Kasper T. Vinten
MTMaria M. Trętowicz
Maria M. Trętowicz
ECEvrim Coskun
Evrim Coskun
MWMichel van Weeghel
Michel van Weeghel
CCCarles Cantó
Carles Cantó
RHRiekelt Houtkooper
Riekelt Houtkooper

26 May 2022 in Molecular Psychiatry
Verified
Journal Article
Closed access
PDF file
Mirolyuba Simeonova IlievaMirolyuba Simeonova Ilieva
Mirolyuba Simeonova Ilieva
BABlanca Irene Aldana
Blanca Irene Aldana
KVKasper Tore Vinten
Kasper Tore Vinten
SHSonja Hohmann
Sonja Hohmann
TWThomas William Woofenden
Thomas William Woofenden
TSTanja Maria Sheldrick-Michel
Tanja Maria Sheldrick-Michel

14 May 2026 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
MTMaria M. TręTowicz
Maria M. TręTowicz
ASAngelique M. L. Scantlebery
Angelique M. L. Scantlebery
BSBauke V. Schomakers
Bauke V. Schomakers
KEKaan D. Eroğlu
Kaan D. Eroğlu
MWMichel van Weeghel
Michel van Weeghel
RHRiekelt Houtkooper
Riekelt Houtkooper

17 February 2026 in The FASEB Journal
Verified
Journal Article
Open access
KVKasper T. Vinten
Kasper T. Vinten
BSBauke V. Schomakers
Bauke V. Schomakers
SDSimone Denis
Simone Denis
MWMichel van Weeghel
Michel van Weeghel
AJAldo Jongejan
Aldo Jongejan
RHRiekelt Houtkooper
Riekelt Houtkooper
Nicotinamide adenine dinucleotide (NAD + ) is a vital molecule, serving as a redox cofactor and the limiting substrate for numerous enzymes. NAD + decline is a key feature of aging, while supplementation with NAD + precursors can efficiently counteract aging traits and prevent age‐associated conditions in preclinical models. However, clinical translation remains challenging, likely due to the limited NAD + boosting capacity of classical precursors, such as nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR). This has brought attention to their reduced forms, reduced NMN (NMNH) and reduced NR (NRH), which are more potent NAD + boosters but remain poorly characterized. Here, we performed a comprehensive comparative analysis using RNA sequencing, proteomics, and metabolomics on cultured murine hepatocytes treated with NMN, NMNH, NR, or NRH. Global metabolic profiling revealed that NRH and NMNH induced substantially broader metabolic alterations than NR and NMN, with NRH uniquely suppressing metabolites involved in energy metabolism. The pronounced metabolic effects were reflected at a transcriptional level, with reduced precursors triggering a significantly higher number of differentially expressed genes than oxidized ones. Shared differentially expressed genes between NMNH and NRH revealed upregulation of stress‐related glutathione‐ S ‐transferases ( Gsts ) which furthermore were reflected in our proteomic profiling. However, the upregulation of Gsts did not cause a depletion of glutathione or oxiglutathione, suggesting a pseudo‐stress response to reduced NAD + precursors. Together, our data demonstrate that reduced NAD + precursors are unique and distinct from the market‐available NAD + precursors NR and NMN, not only as more potent NAD + boosters, but also as compounds influencing a broader range of cellular processes.

25 March 2026 in Nature Communications
Verified
Journal Article
Open access
MRMarie Rumpler
Marie Rumpler
GMGuido van Mierlo
Guido van Mierlo
KVKasper T. Vinten
Kasper T. Vinten
MGMaria Pilar Giner
Maria Pilar Giner
SCStefan Christen
Stefan Christen
CCCarles Cantó
Carles Cantó
NAD+ is a crucial metabolic cofactor whose intracellular levels can influence the progression of multiple metabolic and age-related complications. There is therefore a strong interest in using NAD+ precursors (vitamin B3s) as therapeutic tools, but most current precursors exhibit either poor bioavailability or adverse effects. This study examines the metabolic impact of chronic dietary supplementation with a newly described NAD+ precursor, dihydronicotinamide riboside (NRH), in mice using a comprehensive approach including phenotyping tests, RNA sequencing in different tissues and microbiome analyses. We show that chronic NRH administration at 100 mg/(kg*day) is well tolerated, yet has minimal metabolic effects in mice on a regular diet. However, NRH mitigates high-fat diet-induced metabolic complications when used as a preventive or as a treatment strategy, including improvements in glucose tolerance, increased hepatic expression of lipid catabolism genes and fat redistribution. These results highlight the potential of NRH as a therapeutic agent, although further studies are needed to optimize its use, as higher doses reveal signs of toxicity.